| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA840: Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids in people aged 12 and over (terminated) |
|
Medicine details |
|
| Medicine name | ruxolitinib (Jakavi®) |
| Formulation | 5 mg, 10 mg, 15 mg and 20 mg tablet |
| Reference number | 3287 |
| Indication | Treatment of patients aged 12 years and older with chronic graft versus host disease who have inadequate response to corticosteroids |
| Company | Novartis Pharmaceuticals UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 26/04/2022 |
| NICE guidance | |